Genetic Technologies is a molecular diagnostics company that provides predictive testing and assessment tools to help physicians manage women's health. Co.'s key product, BREVAGenplus, was a clinically validated risk assessment test for non-hereditary breast cancer. Co. has launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. Co. has developed two new cancer risk assessment tests branded as GeneType for Colorectal Cancer and GeneType for Breast Cancer. Co. also develops other risk assessment tests across a range of diseases, including cardiovascular disease, type 2 diabetes, prostate cancer and melanoma. The GENE stock yearly return is shown above.
The yearly return on the GENE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GENE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|